Broad Immune Activity Is Observed With Sotigalimab Combo in Frontline Melanoma
Source: Targeted Oncology, January 2023
Findings from a phase 1/2 trial showed that sotigalimab plus pembrolizumab led to antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.
The humanized IGG1 monoclonal antibody sotigalimab, in combination with pembrolizumab (Keytruda), demonstrated antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma, according to updated phase 1/2 findings presented during the Society for Immunotherapy for Cancer’s (SITC) 37th Annual Meeting.
As of October 28, 2022, the overall response rate (ORR) by RECIST 1.1 criteria among 32 patients on the study (NCT02706353) was 47%, which consisted of a 16% complete response rate and a 31% partial response rate; the stable disease rate was 22% and 31% of patients had progressive disease. The disease control rate was 69%.